01—Abstract
Summary
Summary of the 10-K filed March 10, 2010. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (Nasdaq: EXEL) reported a net loss attributable to Exelixis of $135.2 milliona for the fiscal year ended January 1, 2010, compared with $162.9 million in 2008, while total revenues rose to $151.8 million from $117.9 million.
The increase was driven mainly by the May 2009 sanofi-aventis license and collaboration on XL147 and XL765 and continued recognition of the December 2008 Bristol-Myers Squibb collaboration on XL184 and XL281. Management states that cash and short-term and long-term marketable securities totaled $221.0 millionb at December 31, 2009, and that these resources, together with expected collaborator funding, will sustain operations for at least 12 months after the filing date. The company expects its 2010 net loss to increase over 2009 and anticipates negative operating cash flow for the foreseeable future.
On March 8, 2010, Exelixis implemented a restructuring that reduced its workforce by approximately 40%, or 270 employees, shifting resources toward its lead clinical compounds XL184, XL147 and XL765. The company expects a restructuring charge of approximately $15 millionc in the first quarter of 2010, with additional facility-related and other charges to follow, and the company is still assessing whether to vacate or sublease facilities. Principal risks highlighted include the $85.0 million GlaxoSmithKline loan (of which $70.8 million was outstanding at year-end, with the second and third installments due in October 2010 and 2011), financial covenants tied to working capital and cash and investments, and a Bristol-Myers Squibb co-development provision that could terminate certain rights if cash reserves fall below $80.0 million.
The accumulated deficit stood at $1,089.7 milliond and total stockholders' deficit at $163.7 million as of year-end 2009. The company's strategy centers on XL184, a MET, VEGFR2 and RET inhibit in a global phase 3 registration trial for medullary thyroid cancer, with a possible NDA submission in the second half of 2011, and on the PI3K inhibitors XL147 and XL765, which sanofi-aventis now funds.
02—Key points
Key Highlights
- Total revenues rose to $151.8 million in 2009 from $117.9 million in 2008, driven mainly by the sanofi-aventis collaboration and Bristol-Myers Squibb XL184/XL281 revenue recognition.
- Net loss attributable to Exelixis, Inc. was $135.2 million for 2009, down from $162.9 million in 2008.
- Cash, cash equivalents and marketable securities totaled $221.0 million at December 31, 2009, which management expects to fund operations for at least 12 months after the filing date.
- On March 8, 2010, the company cut its workforce by approximately 40%, or 270 employees, with an expected first-quarter 2010 restructuring charge of approximately $15 million.
- The $85.0 million GlaxoSmithKline loan had $70.8 million outstanding at year-end, with installments due October 27, 2010 and October 27, 2011, and includes working capital and cash-and-investments covenants.
- XL184 is in a global phase 3 registration trial for medullary thyroid cancer; the company expects to submit an NDA in the second half of 2011 if results are positive.
- Accumulated deficit was $1,089.7 million and total stockholders' deficit was $163.7 million at December 31, 2009.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2010filed March 10, 2010Financial Statements
FY2010 against FY2009
| Line item | FY2010FY2009 | Change |
|---|---|---|
| Revenue | $185.04M$151.76M | +21.9% |
| R&D Expenses | $210.68M$234.70M | −10.2% |
| Operating Expenses | $276.44M$273.67M | +1.0% |
| Operating Income | -$91.40M-$121.91M | +25.0% |
| Interest Expense | $9.34M$12.67M | −26.3% |
| Net Income | -$92.33M-$135.22M | +31.7% |
| EPS (Basic) | $-0.85$-1.26 | +32.5% |
| EPS (Diluted) | $-0.85$-1.26 | +32.5% |
| Shares Outstanding (Basic) | 108.52M107.07M | +1.4% |
| Shares Outstanding (Diluted) | 108.52M107.07M | +1.4% |
05—Questions
Frequently Asked Questions
Why did Exelixis's revenue increase in 2009?
The filing attributes the increase primarily to the May 2009 collaboration agreement with sanofi-aventis for PI3K inhibitors, which contributed $46.9 million in revenue, and to $45.9 million of increased revenue from the 2008 Bristol-Myers Squibb collaboration on XL184 and XL281. Boehringer Ingelheim revenue of $10.8 million also contributed, partly offset by lower milestone and contract revenue.
Does Exelixis have enough cash to continue operating?
Management states that its $221.0 million in cash, cash equivalents and marketable securities, plus expected collaborator funding and business development activity, will maintain operations for at least 12 months following the filing date, after giving effect to the March 2010 restructuring. The filing also warns that future capital needs could require earlier use of capital, and that the company may need additional funding to meet loan repayments or covenant requirements.
What is the main risk related to the GlaxoSmithKline loan?
The loan's aggregate principal and interest outstanding was $70.8 million at December 31, 2009. Installments are due October 27, 2010 and October 27, 2011. Repayment may be made in common stock or cash at the company's election, but share-based repayment is limited if the stock price is depressed, which could require additional funding. The loan also carries financial covenants that, if breached, would allow GlaxoSmithKline to accelerate repayment.
What did the March 2010 restructuring involve?
On March 8, 2010, Exelixis reduced its workforce by approximately 40%, or 270 employees, to focus resources on XL184, XL147 and XL765. The reduction was weighted toward the drug discovery group. The company expects a restructuring charge of approximately $15 million in the first quarter of 2010, mainly for one-time termination benefits, plus additional facility-related and other charges that it has not yet estimated.
When might XL184 reach the market?
The company expects to submit a new drug application for XL184 for medullary thyroid cancer in the United States in the second half of 2011, assuming positive results from the ongoing global phase 3 registration trial. It also plans to start a phase 3 trial for recurrent glioblastoma by the end of 2010, assuming positive phase 2 results in that indication.
06—Continue